US FDA shuffles roles at Office of Drug Evaluation 1 to improve decision making
This article was originally published in SRA
Robert Temple is giving up his role as acting director of the US Food Drug Administration's Office of Drug Evaluation 1 (ODE1) so that he can devote more time and his "vast expertise" to his other role as the deputy director for clinical science, the agency has announced1.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.